Clinical trials: Carcinomas
Pathological Complete Remission, Objective Response Rate
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant…
- Conditions
- Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
- Trial name
- NCT07430579
- Testing
- adebrelimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The Second Hospital of Shandong University
Non-small Cell Lung Cancer, Advanced Solid Malignancies
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
This study is to determine the use of theophylline in patients with NSCLC and advanced solid malignancies and whether treatment with theophylline will help lower or diminish the side effect of diarrhea in patients taking…
- Trial name
- NCT02080078
- Testing
- Theophylline, Erlotinib
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- AHS Cancer Control Alberta
Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has…
- Conditions
- Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT02254278
- Testing
- Cisplatin, IMRT 6 weeks, IMRT 5 weeks
- Where
- 222 sites in United States, Canada and 2 more
- Volunteers
- 316 people
- Sponsor
- NRG Oncology
NSCLC Non-small Cell Lung Cancer
Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy (with cisplatin/docetaxel) in primary…
- Trial name
- NCT02572843
- Testing
- MEDI4736 (anti-PD-L1)
- Where
- 19 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Prostate Carcinoma
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively PET-MRI, in patients with prostate cancer.
- Trial name
- NCT02440308
- Testing
- 68Ga-DOTA-Bombesin, Magnetic Resonance Imaging (MRI) scan, Positron Emission Tomography (PET) scan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to…
- Conditions
- Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05256225
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 414 sites in United States, Puerto Rico and 1 more
- Volunteers
- 360 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Neoplasm Metastasis
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
- Conditions
- Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
- Trial name
- NCT00116389
- Testing
- talabostat mesylate tablets, gemcitabine
- Where
- 28 sites in United States
- Volunteers
- 60 people
- Sponsor
- Point Therapeutics
Carcinoma, Non-Small-Cell Lung
Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy
The primary objective of this study is to evaluate the tolerability and the maximum tolerated dose of Conformal or Intensity-Modulated Radiotherapy when given in combination with gefitinib 250mg in Chinese patients with IIIB or…
- Trial name
- NCT00497250
- Testing
- Gefitinib, Radiation Therapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma, Esophagectomy
Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years
To determine whether older patients who underwent esophagectomy had better outcome survival than those who were non-surgically treated.
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophagectomy, Radiotherapy, Chemotherapy
- Trial name
- NCT05604950
- Testing
- Since the data were collected retrospectively, there were no interventions
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Yongtao Han
Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor…
- Trial name
- NCT07107750
- Testing
- Emavusertib, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Nasopharyngeal Carcinoma
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone…
- Trial name
- NCT05340491
- Testing
- Toripalimab, Chemotherapy, Intensity modulated radiotherapy
- Where
- 12 sites in China
- Volunteers
- 212 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma
Radiotherapy is an important treatment for initial distant metastases nasopharyngeal carcinoma. Total dose and fraction size are important prognostic factors for survival, although to our knowledge the optimal model has not been…
- Trial name
- NCT03598218
- Testing
- Hypofraction radiation, Standard dose IMRT
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Wei Jiang
Papillary Thyroid Carcinoma
APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.
To determine the improvement in diagnosis of papillary carcinoma by detecting mutation V600E BRAF in retrospective cases with inconclusive cytologic diagnosis (categories III, IV and V of Bethesda System)
- Trial name
- NCT02323724
- Testing
- BRAF V600E mutation by pyrosequencing technique
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Corporacion Parc Tauli
Head and Neck Carcinoma
Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer
This randomized clinical trial studies how well Nestle Impact Advanced Recovery works in improving surgery recovery in patients with head and neck cancer.
- Trial name
- NCT03261180
- Testing
- Best Practice, Laboratory Biomarker Analysis, Nutritional Intervention
- Where
- United States
- Sponsor
- OHSU Knight Cancer Institute
Bowen's Disease, Cutaneous Squamous Cell Carcinoma in Situ
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease).
- Trial name
- NCT04293679
- Testing
- STP705
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sirnaomics
Non Small Cell Lung Cancer
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose…
- Trial name
- NCT04866017
- Testing
- Tislelizumab, Durvalumab, Ociperlimab
- Where
- 35 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- BeiGene
Endometrial Cancer
Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma
Endometrial cancer (EC) is the most frequent gynecological malignancy but there is currently lack of both non-invasive diagnostic tools and novel markers to stratify patients based on their risk of future recurrence.
- Trial name
- BioEndoCar (NCT03553589)
- Testing
- Blood sampling
- Where
- 5 sites in Netherlands, Poland and 1 more
- Volunteers
- 400 people
- Sponsor
- Andrea Romano
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with…
- Trial name
- NCT01199068
- Testing
- CS-7017, Erlotinib
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Hepatocellular Carcinoma, Recurrent Cancer
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the…
- Conditions
- Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant
- Trial name
- NCT04204850
- Testing
- Cabozantinib
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Non-Small-Cell Lung Cancer
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03728374
- Testing
- Anlotinib
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.